The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency

@article{Terrell2005TheIO,
  title={The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency},
  author={D R Terrell and Lauren A. Williams and S K Vesely and Bernhard L{\"a}mmle and Johanna A. Kremer Hovinga and James N George},
  journal={Journal of Thrombosis and Haemostasis},
  year={2005},
  volume={3}
}
Summary.  Background: Accurate estimates of the incidence of thrombotic thrombocytopenic purpura (TTP) are important to assess the resources required for current treatments as well as to anticipate the need to develop new treatments. Previous estimates have been indirect and have not reported data on patients with ADAMTS‐13 deficiency. Objective: To determine the incidence of patients with TTP‐hemolytic uremic syndrome (HUS) in three categories: all patients with clinically suspected TTP‐HUS… Expand
Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpura‐Hemolytic Uremic Syndrome Registry
TLDR
The Oklahoma TTP‐HUS Registry is an inception cohort of consecutive patients for whom plasma exchange treatment was requested for a diagnosis of either TTP or hemolytic uremic syndrome and data have provided new perspectives on the definition and diagnoses of these syndromes as well as their outcomes. Expand
Systemic infections mimicking thrombotic thrombocytopenic purpura
TLDR
Initial plasma exchange treatment is appropriate in critically ill patients with diagnostic features of TTP, even if a systemic infection is suspected, but continuing evaluation to document a systemic infections is essential to determine the appropriateness of continued plasma exchange. Expand
The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007).
  • J. George
  • Medicine
  • Kidney international. Supplement
  • 2009
The Oklahoma TTP (thrombotic thrombocytopenic purpura)-HUS (hemolytic uremic syndrome) Registry, an inception cohort of 382 consecutive patients with TTP-HUS, provides a complete communityExpand
How I treat patients with thrombotic thrombocytopenic purpura: 2010.
TLDR
A subgroup of patients who appear to benefit from treatment with corticosteroids and other immunosuppressive agents in addition to plasma exchange but who have a high risk for relapse are defined. Expand
Analysis of clinical and laboratory characteristics in 42 patients with thrombotic thrombocytopenic purpura from a single center in China.
  • M. Deng, Guang-sen Zhang, +6 authors Jian-kai Shen
  • Medicine
  • Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2013
TLDR
The diagnosis of TTP in China is still based on clinical features including evidence of microangiopathic hemolysis, and severe ADAMTS 13 activity deficiency might be a valuable indicator for idiopathics TTP diagnosis. Expand
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports.
TLDR
It is suggested that in some patients pancreatitis, a disorder that results in an intense systemic inflammatory response, may be a triggering event for acute episodes of TTP-HUS. Expand
The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals.
TLDR
TTP/HUS is a challenging diagnosis in obstetric triage and ED areas and a management scheme is proposed that suggests how to triage patients for early diagnosis in pregnancy. Expand
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan
TLDR
The monoclonal anti-CD-20 antibody rituximab is effective in patients with refractory or relapsed TTP and corticosteroid therapy may be administered in conjunction with plasma exchange to suppress autoantibody production. Expand
Survival and relapse in patients with thrombotic thrombocytopenic purpura.
TLDR
The Oklahoma TTP Registry is a population-based inception cohort of all 376 consecutive patients with an initial episode of clinically diagnosed TTP, and ADAMTS13 deficiency during remission was not clearly related to subsequent relapse. Expand
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes
TLDR
Observations of different gender and race disparities among the TTP‐HUS syndromes suggest the presence of different risk factors and may serve as starting points for novel investigations of pathogenesis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.
TLDR
The data suggest that severe ADAMTS-13 deficiency does not detect all patients who may be appropriately diagnosed with TTP-HUS and who may respond to plasma exchange treatment. Expand
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
TLDR
Severe ADAMTS13 deficiency does not detect all patients who may be appropriately diagnosed with TTP-HUS and who may respond to plasma exchange treatment, and many patients in all ADAMts13 activity categories apparently responded to Plasma exchange treatment. Expand
The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults.
TLDR
The majority of patients who developed acute renal failure and survived to hospital discharge recovered renal function and became independent of dialysis and could not be predicted based on admission biochemical or clinical variables. Expand
How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
TLDR
Although the increased survival rate is dramatic and recent advances in understanding the pathogenesis of these syndromes are remarkable, clinical decisions remain empirical, and the management decisions for patients with suspected TTP-HUS rely on individual experience and opinion, resulting in many different practice patterns. Expand
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
TLDR
The results indicate that a deficiency of von Willebrand factor-cleaving protease alone is not sufficient to cause acute TTP, and a new classification of thrombotic microangiopathy should replace the current, frequently inappropriate clinical discrimination between TTP and haemolytic uraemic syndrome. Expand
Incidence of Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome
TLDR
The incidence of thrombotic thromBocytopenia purpura and hemolytic uremic syndrome is higher than previously reported but does not appear to be rising. Expand
The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome
  • J. George
  • Medicine
  • Current opinion in hematology
  • 2003
TLDR
The occurrence of preeclampsia and related syndromes, the hypercoaguable state that occurs in late pregnancy and postpartum, and the progressively decreasing concentration of ADAMTS13 that occurs during late pregnancy may combine to increase the risk for occurrence of thrombotic throm bocytopenic purpura–hemolytic uremic syndrome. Expand
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
TLDR
Assays of ADAMTS13 activity and inhibitors in addition to the clinical categories (idiopathic TTP and nonidiopathy TTP) are predictive of outcome and may be useful to tailor patient treatment. Expand
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.
TLDR
The study showed that ADAMTS13 activity is decreased in a substantial proportion of patients with thrombocytopenia of various causes. Expand
Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991
TLDR
This work analyzed U.S. multiple cause‐of‐death mortality data with TTP listed on the death record for the period 1968–1991 to estimate the incidence of TTP, to characterize demographic features of the decedents, and to determine if trends in mortality correlate with findings from clinical studies showing improved survival in recent years. Expand
...
1
2
3
...